Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation

- Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

- Zhong, Michael, van der Walt, Anneke, Macdonell, Richard, Prevost, Julie, Kuhle, Jens, Laureys, Guy, Van Hijfte, Liesbeth, Alroughani, Raed, Kermode, Allan G., Butler, Ernest, Barnett, Michael, Eichau, Sara, Stankovich, Jim, van Pesch, V, Grammond, P, McCombe, P, Karabudak, R, Duquette, P, Girard, M, Taylor, B, Yeh, W, Monif, M, Gresle, M, Kalincik, Tomas, Butzkueven, H, Jokubaitis, VG, Buzzard, Katherine, Skibina, Olga, Boz, Cavit, Hodgkinson, Suzanne, Slee, Mark, Lechner-Scott, Jeanette